As tumor-infiltrating lymphocytes (TILs) are proven to be a stable and ideal biomarker for response to PD-1 blockade immunotherapy, we evaluated the CD8A RNA levels in the HPV-positive and -negative groups based on gene profiles from the TCGA and GSE40774 cohorts. The gene discussed is PDCD1; the disease is neoplasm.